A new study reports that a receptor targeted for treating neurodegenerative diseases also appears to play an important role in supporting the retina.
A drug usually used for the treatment of multiple sclerosis appears to increase the activity of Nrf2, a protein that protects the body from oxidative stress and inflammation associated with Parkinson's disease.
Activating Nrf2 helps with the removal of LRRK2 and alpha synuclein, researchers report.
A new study sheds light on how the circadian clock controls inflammatory response. By understanding the link between inflammation and circadian rhythm, researchers believe it may be most effective to target specific conditions at certain times of the day. The findings may also explain why those who experience body clock disruptions are more susceptible to inflammatory conditions.
Researchers report UroA, a microbial metabolite derived from a compound found in pomegranates and berries, can reduce and protect against inflammatory bowel disease.
Fish model study found a potential target for the treatment of seasonal affective disorder (SAD). Researchers implicated NRF2 in seasonal depression and reported celastrol may help in the treatment of SAD.
Bach1, a protein that blocks the expression of genes associated with neuroprotection, has been implicated in Parkison's disease. Researchers say blocking Bach1 slows the deterioration of brain cells in preclinical models of Parkinson's disease.
Carnosic acid, a compound found in the herb rosemary, can block the interaction with the COVID-19 SARS_CoV_2 spike protein and ACE2, the protein receptor the virus uses to gain access into cells. The compound appears to have anti-inflammatory effects and has previously been associated with a reduction in Alzheimer's symptoms.